News and Announcements
Universal Biosensors H1 2016 Results, Presentation and Audio Presentation
- Published July 22, 2016 10:23AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
21st July 2016, ASX Announcement
Highlights:
- Total revenue of $10.5 million in 1H16, up 41% on1H15
- Revenue from Quarterly Service Fees – generated by sales of glucose test strips – $10.3 million, up 58% on 1H15
- Net loss of $1.2 million, improvement from 1H15 net loss of $4.1 million and trending towards breakeven
- R&D expenditure $7.9, down 20% on 1H15 due to refocus of product development pipeline and containing costs
- Cash balance of $13.2 million, up from $10.7 million
Universal Biosensors (ASX:UBI) today released its financial results for the first half of 2016.
To view the full announcement, please click on the button below.
To view the Presentation, please click on the button below.
To view the Audio Presentation, please click on the button below.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
